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Abstract Background: Lesogaberan (AZD3355) is a novel reflux inhibitor developed as
an add-on treatment to proton pump inhibitors (PPIs) for symptom relief in
patients with gastroesophageal reflux disease who have a partial response to
PPI therapy.
Objective: The aim of this study was to evaluate the pharmacokinetic profile
of lesogaberan in healthy subjects after single oral and intravenous adminis-
tration of 14C-labeled lesogaberan and non-14C-labeled lesogaberan.
Study Design: This was an open-label, single-center, randomized, two-way
crossover, phase I study.
Participants: Ten healthy male subjects took part in the study.
Intervention: Volunteers were randomized to receive a single dose of either
orally dosed (100mg) or intravenously infused (20mg) non-14C-labeled
lesogaberan, and then orally (100mg) or intravenously (20mg) administered
14C-labeled lesogaberan in a crossover design. Treatment periods were sep-
arated by a washout period of at least 7 days.
Main Outcome Measures: Analyses of the rate and route of excretion, dose
recovery, area under the plasma concentration versus time curve (AUC),
AUC to the last quantifiable concentration, maximal plasma concentration
(Cmax), time to Cmax, the apparent elimination half-life, bioavailability, total
clearance, renal clearance, fraction of the bioavailable dose excreted un-
changed in the urine, cumulative amount of drug excreted unchanged in
urine, and the apparent volume of distribution at steady state of lesogaberan.
Results: Lesogaberan was rapidly and extensively absorbed from the gastro-
intestinal tract and Cmax was achieved within 1–2 hours of oral dosing. The
terminal half-life of lesogaberan was between 11 and 13 hours. Renal clear-
ance accounted for approximately 22% of total body clearance. Based on the
recovery of administered radioactivity, approximately 84% of the dose was
excreted into the urine either as the parent compound or as water-soluble
metabolite(s). There were no safety concerns raised during the study.
Conclusion: Orally administered lesogaberan is rapidly absorbed with high
bioavailability and the majority of the dose is excreted by the kidneys either as
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the parent compound or as metabolites. The major elimination pathway for
lesogaberan in man is metabolism.
Introduction
Pharmacologic agents such as GABAB receptor
agonists (e.g. baclofen) have been shown to inhibit
transient lower esophageal sphincter relaxations
(TLESRs), a major cause of reflux events in both
healthy subjects and patients with gastroesophageal
reflux disease (GERD).[1,2] As such, GABAB ago-
nists offer a rational therapeutic add-on treatment
to proton pump inhibitors (PPIs) for patients
with GERD who have a partial response to PPIs,
which is the current standard of care forGERD.[3]
Lesogaberan (AZD3355) is a primarily periph-
erally restrictedGABAB receptor agonist
[4] that has
previously been shown to inhibit the frequency of
TLESRs in both healthy subjects[5] and patients
with GERD.[6] In the latter pharmacodynamic
study in GERD patients,[6] for example, lesoga-
beran at an oral dose of 65mg twice daily reduced
the mean number of reflux events by approximately
35% versus placebo. A subsequent phase II study
in GERD patients attests to the potential clinical
efficacy of lesogaberan at this dose.[7] The aim of
the present study, therefore, was to further inves-
tigate the pharmacokinetic profile of lesogaberan,
including the rate and route of excretion of total
radioactivity following oral and intravenous dosing
with 14C-labeled and non-14C-labeled lesogaberan.
A secondary objective of the study was to assess
the safety and tolerability of lesogaberan in terms
of adverse events, blood pressure, pulse rate,
electrocardiography, physical examination, and
laboratory safety testing.
Subjects and Methods
This was a phase I, open-label, randomized, two-
way crossover study (study code: D9120C00017) to
evaluate the pharmacokinetic profile of lesoga-
beran after oral and intravenous administration
in healthy subjects. The study was conducted at a
single center in theUK, in accordance with ethical
principles and standards described in the Decla-
ration of Helsinki and the International Conference
on Harmonisation (ICH)/Good Clinical Practice
(GCP) guidelines, and was approved by an in-
dependent ethics committee. Written informed
consent was obtained from all subjects prior to
the commencement of the study.
Study Population
Healthy male subjects aged 35–55 years with
a bodyweight of 65–100 kg, a body mass index of
19–30 kg/m2, and clinically normal physical find-
ings and laboratory values were eligible for in-
clusion. In order to ensure safety, subject exclusion
criteria included (i) significant clinical illness oc-
curring in the 2 weeks prior to the study; (ii) his-
tory of mental, cardiac, renal, hepatic, neurologic,
or significant gastrointestinal disease; (iii) a history
of, or ongoing hypersensitivities; (iv) a history of
gallstones; or (v) any condition/concomitant med-
ication that could potentially modify the pharma-
cokinetics of the study drug.
Study Design and Treatments
The study design is presented in figure 1. At the
pre-entry screening visit, subjects were provided
with information about the study and informed
consent was collected. Following the pre-study
screening visit, the study consisted of two treatment
periods separated by a washout of at least 7 days.
In the first treatment period (72 hours in-house
stay), subjects were randomized (50 : 50 ratio) to
receive either lesogaberan dosed orally (100mg)
or intravenously (20mg, 75 minute infusion of a
2mg/mL solution). The solution for injection was
used for both oral and intravenous dosing and
administered to fasted subjects (overnight fast).
The oral dosewas administeredwith approximately
200mL of water. Standardized meals and snacks
were provided during the stay at the study center.
On the second dosing occasion (168 hours
in-house stay), all subjects received 14C-labeled
lesogaberan in a crossover design under conditions
similar to the first treatment period (i.e. subjects
who previously received orally administered leso-
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gaberan received intravenously administered le-
sogaberan and vice versa). Subjects only received
one dose of 14C-labeled lesogaberan during the
study to minimize exposure risk and to remain
within the guidance of WHO category I study
limits of radioactivity. Standardized meals and
snacks were provided during the stay at the study
center, as for the first treatment period.
A post-study follow-up visit was scheduled
5–7 days after discharge from the second treat-
ment period or early discontinuation.
Sample Collection
Blood samples (2mL) for the determination of
plasma lesogaberan concentrations were collected
during both treatment periods after oral (sam-
pling times: 0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4,
6, 8, 12, 18, 24, 36, 48, 60, and 72 hours post-dose)
and intravenous (sampling times: 0, 0.08, 0.25,
0.5, 0.75, 1, 1.25, 1.33, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8,
12, 18, 24, 30, 36, 48, 60, and 72 hours post-dose)
administration. Additional blood samples for the
determination of total radioactivity (sampling
times: 96, 120, 144, and 168 hours post-dose) were
taken during the second treatment period after
both oral and intravenous administration.
Urine samples for the determination of urine
lesogaberan concentrations were collected from
pre-dose until 72 hours post-dose during both
treatment periods in the following time intervals:
pre-dose, 0–4, 4–8, 8–12, 12–24, 24–48, and
48–72 hours post-dose. Additional samples were
collected during the second treatment period in
24-hour time intervals from 72 to 168 hours post-
dose. Urine was sampled for 216 hours post-dose
for the determination of total radioactivity.
Fecal samples for the determination of total
radioactivity were collected from pre-dose to
216 hours after dose intake.
Further study procedures during both treat-
ment periods included assessments of electro-
cardiography, blood pressure, and pulse at pre-dose,
1 hour, and 24 hours post-dose, safety laboratory
tests at pre-dose and 24 hours post-dose, and
daily recording of adverse events.
Information regarding the metabolic profile,
quantification of metabolites, and metabolite identi-
fication of lesogaberan in excreta and plasma sam-
ples will be presented in a subsequent publication.
Analytical Methods
Plasma and urine samples for analysis of lesoga-
beran concentrations were stored and shipped at less
than -20C. Samples were analyzed by an accred-
ited laboratory (PRA International-Bioanalytical
Laboratory B.V., Assen, the Netherlands) by
liquid chromatography and mass spectrometric
detection (lower limits of quantification were
0.03 mmol/L [plasma] and 1.00 mmol/L [urine])
within a timeframe and protocol consistent with
previously established stability and analytical
data. The total radioactivity in plasma, urine, and
feces was analyzed at and reported by Covance
Laboratories Limited (Harrogate, UK) accord-
ing to a previously validated protocol.
The lower limit of quantification (LLOQ) of
total radioactivity in the plasma samples was based
upon the radioactive concentration of the back-
ground value (determined from pre-dose plasma
samples), the weight of the sample taken, and the
specific radioactivity of the dose formulation.
For excreta samples, the LLOQ was taken as twice
the background disintegrations per minute value
of the corresponding pre-dose sample type.
Pharmacokinetic and Statistical Methods
The sample size was based on previous pharma-
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Fig. 1. Study design. IV = intravenous; R = randomization.
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sample-size calculations were performed. De-
scriptive statistics were calculated for all phar-
macokinetic and safety variables using SAS
(version 8.2).
The following pharmacokinetic variables were
estimated for lesogaberan by non-compartmental
methods using WinNonlin Enterprise version 4.1
(Pharsight Corporation, Mountain View, CA,
USA): total area under the plasma concentration
versus time curve (AUC); AUC from time zero
until the last quantifiable concentration (AUCt);
observed maximum plasma concentration (Cmax);
the time to reach Cmax (tmax); terminal plasma
half-life (t½); oral bioavailability (F); total body
clearance (CL); renal clearance (CLR); fraction of
dose excreted unchanged into the urine following
intravenous administration; cumulative amount
of the drug excreted unchanged in the urine (fol-
lowing intravenous administration only); and the
apparent volume of distribution at steady-state
(Vss). The amounts of total radioactivity in the
urine and feces (expressed as a percentage of the
dose) were also calculated.
Estimates and 95% confidence intervals (CIs)
of the true geometric means were calculated for
AUC, AUCt, Cmax, t½, F, CL, CLR and Vss
(arithmetic mean was calculated for tmax). For the
cumulative amount of the drug excreted unchanged
in the urine and the fraction of the dose excreted
unchanged into the urine, estimates and CIs of
the true geometric means, or estimates and CIs of
the true means were calculated depending on the
observed frequency distribution.
Results
A total of ten subjects were enrolled in the study
and randomized to treatment. All subjects com-
pleted the study and were included in both the
pharmacokinetic and safety analyses. A summary of
subject baseline characteristics is presented in table I.
The estimated geometric mean pharmacokinetic
variables for orally and intravenously administered
lesogaberan for the whole study population (n= 10)
are presented in table II. The oral bioavailability
of lesogaberan was high (F = 0.67). Following
intravenous administration, Vss and CL of leso-
gaberan were 208.7L and 22.9L/hour, respectively.
CLR accounted for 5.2 L/hour of total clearance;
a total of 31.2 mmol, or 22.6% of the dose, was
excreted unchanged into the urine following in-
travenous administration. CLR of lesogaberan
following oral and intravenous dosing was sim-
ilar, as was the amount excreted unchanged into
the urine following adjustments for dose and
bioavailability.
The pharmacokinetic variables calculated from
14C-labeled lesogaberan data (table III) were
similar to those for non-14C-labeled lesogaberan.
The pharmacokinetic profiles of orally and intra-
venously dosed 14C-labeled lesogaberan are pre-
sented in figure 2.
The mean (– SD) recovery of total radioactivity,
expressed as a percentage of the total dose, from
the urine and feces over a 216-hour sampling
period following oral dosing of lesogaberan was
84.2– 5.6% and 9.0– 1.5%, respectively. The cor-
responding values for intravenously administered
lesogaberan were 83.9 – 2.3% and 7.1 – 1.3%, re-
spectively. The renal elimination and fecal ex-
cretion of radioactivity were almost complete after
216 hours and 168 hours, respectively. Plasma
concentrations for total radioactivity were higher
than those of lesogaberan throughout the ma-
jority of the sampling period, and thus indicate
the presence of circulating metabolite(s).
In total, nine of ten subjects reported 22 ad-
verse events during active treatment (table IV).
All of the adverse events were transient and mild
to moderate in intensity. The most frequently
reported adverse events that were experienced by
more than one subject in each treatment group
were paresthesia (short-lasting cutaneous sensa-
tions: oral administration, n = 6; intravenous
administration, n= 8) and headache (oral admin-
istration, n= 2; intravenous administration, n= 2).
There were no serious adverse events, adverse
Table I. Subject baseline characteristics (n = 10)
Characteristic Mean –SD Range
Age (y) 47.2 –3.4 43–54
Height (cm) 179.4 –6.6 169–187
Bodyweight (kg) 84.4 –13.2 62–99
Body mass index (kg/m2) 26.1 –2.6 21.7–28.6
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events leading to study discontinuation, or clin-
ically relevant changes in vital signs, ECG, or
physical findings throughout the study.
Discussion
This is the first study to report on the pharma-
cokinetic profile, including routes of excretion,
of orally and intravenously administered lesoga-
beran in humans. An oral dose of 100mg was
chosen for study in accordance with the predicted
dose range because the therapeutic dose has not
yet been established. Results show that lesogaberan
was readily absorbed from the gastrointestinal
tract following oral administration, with a termi-
nal plasma half-life of 11.2 hours. The estimates
of bioavailability, Vss, CL, and the fraction of the
dose of lesogaberan excreted unchanged into the
urine were in-line with the results of previous
early-stage clinical studies.[8] A relatively large Vss
(approximately 200L), coupled with no binding
to plasma proteins,[9] indicates that lesogaberan
demonstrates extensive distribution in the tissues.
Overall, the main conclusion of the present study
is that the major route of elimination (clearance
of parent compound in this case) is metabolism.
While further studies are planned to determine
the metabolic pathway and metabolites of leso-
gaberan, it is apparent that the kidney represents
themajor route of clearance of drug-relatedmaterial
Table II. Estimated geometric means and 95% CIs for the pharmacokinetic variables of lesogaberan (n = 10)
Variable Oral administration (100mg) Intravenous administration (20mg)
geometric mean 95% CI geometric mean 95% CI
AUC (mmolh/L) 20.7 17.2, 24.9 6.0 5.2, 7.0
AUCt (mmolh/L) 19.9 16.4, 24.1 5.3 4.5, 6.3
Cmax (mmol/L) 2.5 1.9, 3.3 2.35 2.0, 2.7
tmax (h)
a 1.2 0.9, 1.4 1.2 1.1, 1.3
t½ (h) 11.2 10.7, 11.8 13.0 11.2, 15.1
Vss (L) NA NA 208.7 167.4, 260.0
CL (L/h) NA NA 22.9 20.1, 26.1
CLR (L/h) 5.14 4.5, 5.8 5.2 4.7, 5.7
Ae (mmol) 106.3 83.5, 135.4 31.2 28.0, 34.8
fe (%) NA NA 22.6 20.5, 24.9
Bioavailability 0.67 0.6, 0.7 NA NA
a Arithmetic mean.
Ae = cumulative amount of drug excreted unchanged into the urine; AUC = total area under the plasma concentration vs time curve;
AUCt =AUC from time zero to the time of last quantifiable concentration; CL = total clearance; CLR = renal clearance; Cmax =maximum plasma
concentration; fe = fraction of dose excreted unchanged into the urine; NA =not applicable; t½ =elimination half-life; tmax = time to Cmax;
Vss= apparent volume of distribution at steady state.
Table III. Estimated geometric means and ranges for the pharmacokinetic variables of 14C-labeled lesogaberan dosed orally (n = 5) and
intravenously (n= 5)
Variable Oral administration (100mg) Intravenous administration (20mg)
geometric mean range geometric mean range
AUC (mmolh/L) 22.1 16.6–31.9 6.0 5.0–7.8
AUCt (mmolh/L) 21.3 16.2–31.3 5.2 4.0–7.2
Cmax (mmol/L) 3.0 1.8–5.4 2.3 1.9–2.5
t½ (h) 11.1 9.4–11.9 14.6 11.2–19.8
tmax (h)
a 1.2 1.0–2.0 1.2 1.0–1.4
a Arithmetic mean.
AUC = total area under the plasma concentration vs time curve; AUCt=AUC from time zero to the time of last quantifiable concentration;
Cmax =maximum plasma concentration; t½=elimination half-life; tmax = time to Cmax.
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because 84% of administered radioactivity was
excreted into the urine either as the parent com-
pound or as water-soluble metabolite(s). CLR of
lesogaberan following intravenous administration,
however, only accounted for approximately 22%
of CL. Plasma concentrations of total radio-
activity were also higher than lesogaberan plasma
concentrations during a significant proportion of
the sampling period. Together, such findings in-
dicate that metabolism is a presumed major route
of elimination, followed by renal clearance of
drug-related material, and further studies are
planned to investigate the metabolic disposition
of lesogaberan in terms of specific metabolic
pathways. Further research may also be war-
ranted to determine the effect of renal and hepatic
impairment on the disposition of lesogaberan
because this will be relevant for clinical use.
Previous studies in humans were used to deter-
mine the duration of the biologic sampling periods
to ensure that virtually no radioactive lesoga-
beran remained to be excreted after the sampling
was completed.[8] The oral dose (100mg) was se-
lected on the basis that this dose level is expected
to be within the range of therapeutic doses.[7] The
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Fig. 2. Mean (– SD) plasma concentration versus time profiles of orally (100mg) and intravenously (20mg) administered 14C-labeled leso-
gaberan (n =5).
Table IV. Number of subjects with adverse events after oral and intravenous administration of 14C-labeled and non-14C-labeled lesogaberan
(n= 10)a
Adverse event Oral administration (100mg) Intravenous administration (20mg)
Paresthesia 6 (6) 8 (8)
Headache 2 (2) 2 (2)
Feeling hot 1 (1) 0 (0)
Pain 0 (0) 1 (1)
Diarrhea 0 (0) 1 (1)
Sensation of heaviness 0 (0) 1 (1)
a Numbers in parentheses indicate the number of adverse events.
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yield a similar maximal plasma concentration but
lower total systemic exposure, compared with the
oral dose.
Both the oral and intravenous doses of lesoga-
beran were well tolerated, and neither dosing regi-
mens raised any safety concerns. This finding, albeit
limited by the small size of the study, is in-line with
those of previous studies that reported that lesoga-
beran iswell tolerated in oral doses of up to 500mg.[8]
Conclusion
In this study in healthy subjects, lesogaberan
administered orally was rapidly absorbed with high
bioavailability, extensively metabolized (based on
clearance of the parent compound), and the ma-
jority of the dose was excreted by the kidneys
either as the parent compound or as water-soluble
metabolites.
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